Barbut F, Collignon A, Butel M-J, Bourlioux P
Laboratoire Clostridium difficile associé au CNR des anaérobies et du botulisme, unité du lutte contre les infections nosocomiales (UHLIN), hôpital Saint-Antoine, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France; Groupe de recherche clinique n(o) 2 EPIDIFF, université Pierre-et-Marie-Curie, 75012 Paris, France.
EA4043, faculté de pharmacie, université Paris Sud, 92290 Châtenay-Malabry, France; Service de microbiologie, hôpital Jean-Verdier, AP-HP, 93140 Bondy, France.
Ann Pharm Fr. 2015 Jan;73(1):13-21. doi: 10.1016/j.pharma.2014.05.004. Epub 2014 Jun 19.
Fecal microbiota transplantation (FMT) has gained an increasing medical interest, since the recognition of the role of disturbed microbiota in the development of various diseases. To date, FMT is an established treatment modality for multiple recurrent Clostridium difficile infection (RCDI), despite lack of standardization of the procedure. Persisting normalization of the disturbed colonic microbiota associated with RCDI seems to be responsible for the therapeutic effect of FMT. For other diseases, FMT should be considered strictly experimental, only offered to patients in an investigational clinical setting. Although the concept of FMT is appealing, current expectations should be damped until future evidence arises.
自从认识到微生物群紊乱在各种疾病发生发展中的作用以来,粪便微生物群移植(FMT)在医学上受到了越来越多的关注。迄今为止,尽管该操作缺乏标准化,但FMT仍是治疗多次复发性艰难梭菌感染(RCDI)的既定治疗方式。与RCDI相关的紊乱结肠微生物群持续恢复正常似乎是FMT治疗效果的原因。对于其他疾病,FMT应被视为严格意义上的实验性治疗,仅在临床研究环境中提供给患者。尽管FMT的概念很有吸引力,但在有更多证据之前,目前的期望应有所降低。